Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations of the p16 gene product are rare in prostate cancer.

The Prostate - 15 Feb 1997

Gaddipati J P, McLeod D G, Sesterhenn I A, Hussussian C J, Tong Y A, Seth P, Dracopoli N C, Moul J W, Srivastava S

Abstract excerpt

BACKGROUND: The p16 gene product is a negative regulator of cell cycle and has been shown to be deleted or mutated in a number of tumor cell lines and primary tumors. The role of p16 in prostate cancer is not defined. Prostate cancer tissues and cell lines were evaluated for p16 gene alterations. METHODS: Five metastatic prostate cancer cell lines were analyzed for p16 gene structure and its expression by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Probes
Share to Mutation
Share to Blotting, Northern

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Blotting, Southern

Share to Carrier Proteins

Share to DNA, Neoplasm

Share to Polymerase Chain Reaction

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 9122044
DOI: 10.1002/(sici)1097-0045(19970215)30:3<188::aid-pros7>3.0.co;2-i

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations of the p16 gene product are rare in prostate cancer.PMID 9122044Read ↗

p16 mutations/deletions are not frequent events in prostate cancer.Semantic proximity Read ↗

Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancerSemantic proximity Read ↗

Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancersSemantic proximity Read ↗

Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition.Semantic proximity Read ↗

Alterations of the retinoblastoma gene in human prostate adenocarcinomaSemantic proximity Read ↗

Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma.Semantic proximity Read ↗

Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.Semantic proximity Read ↗

Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors.Semantic proximity Read ↗

Deletion of the p16 and p15 Genes in Human Bladder TumorsSemantic proximity Read ↗

Role of the p16 tumor suppressor gene in cancer.Semantic proximity Read ↗

Retinoblastoma gene mutations in primary human prostate cancer.Semantic proximity Read ↗

Mutation analysis of the BRG1 gene in prostate cancer clinical samples.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.